February’s trending topics included a look at the past, present and future of transcatheter aortic valve implantation (TAVI) with two of the procedure’s pioneers, Alain Cribier (Rouen, France) and Michael Reardon (Houston, Texas), as well as an important development in the use of renal denervation for resistant hypertension.
- TAVI pioneers discuss the past, present and future of transcatheter therapy
As transcatheter aortic valve implantation (TAVI) moves beyond its 20-year milestone, two pioneers of the treatment—Alain Cribier (University Hospital of Rouen, Rouen, France) and Michael Reardon (Academic Institute Methodist DeBakey Heart & Vascular Center, Houston, USA)—reflect on its wide-reaching impact on the treatment of aortic disease. - TruLeaf Medical to trial “two-stage” TMVR platform
TruLeaf Medical is to conduct a first-in-human clinical trial of a “two-stage” transcatheter mitral valve replacement (TMVR) procedure, it has been announced. - ESC and EAPCI publish renal denervation consensus statement
Renal denervation represents another treatment option in patients with uncontrolled resistant hypertension and may be used in selected patients deemed intolerant to antihypertensive drugs. - The interventional cardiology trials to watch in 2023
Mirvat Alasnag (King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia), Roxana Mehran (Mount Sinai Hospital, New York, USA) and Suzanne Baron (Lahey Hospital & Medical Center, Burlington, USA) who spoke to Cardiovascular News about the trials they are expecting to have the most impact throughout the year. - Medtronic relaunches Harmony transcatheter pulmonary valve
Medtronic has announced the relaunch of its Harmony transcatheter pulmonary valve (TPV) system, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT). - ADVERTORIAL: A wealth of data underscore treatment choices for coronary DCBs
Tuomas Rissanen (North Karelia Central Hospital, Joensuu, Finland) discusses the evolution of drug-coated balloons (DCBs) an effective alternative to the stent that offers a range of benefits in selected patients with coronary artery disease. - Poor, irregular sleep linked to increased atherosclerosis in adults 45 and above
Sleeping an inconsistent number of hours each night and falling asleep at different times may increase the risk of developing atherosclerosis among adults older than 45 compared to people with more consistent sleep habits, according to new research published in the Journal of the American Heart Association. - Teleflex grows catheter portfolio following US FDA approval
Teleflex Incorporated has announced key milestones in the release of two new catheters, including the US Food and Drug Administration (FDA) 510(k) clearance of the Triumph catheter, and the first clinical use of GuideLiner Coast catheter. - ADVERTORIAL: DCB therapy offers a glimpse of interventional cardiology’s past and future
Raban Jeger (University Hospital Basel, Basel, Switzerland) and Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant’Ambrogio, Milan, Italy) explain why they see drug-coated balloons as an important tool in the armoury for percutaneous coronary intervention (PCI). - PROFILE: Nieves Gonzalo
Nieves Gonzalo (Clinico San Carlos University Hospital, Madrid, Spain), a course director for EuroPCR, deputy editor of EuroIntervention, and co-chair of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Scientific Documents and Initiatives Committee, tells Cardiovascular News about her career to date, research priorities, and the importance of representation.
